Global Alzheimer's Treatment Market Report and Forecast 2025-2034

Global Alzheimer's Treatment Market Outlook

The global Alzheimer’s treatment market is expected to grow at a CAGR of 7.2% in 2025-2034 and is projected to reach about 105.91 billion USD by 2034. The market is driven by the increased elderly population and increasing immune disorders are the major cause of the disease's high prevalence. Another vital factor projected to influence the industry growth is the increasing government investment for improved support and care for those with progressive Alzheimer’s.

 Another vital factor projected to influence the industry growth is the increasing government investment for improved support and care for those with progressive Alzheimer’s.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Alzheimer’s Disease Insights

Alzheimer's disease is among the most prominent form of dementia, a type of progressive cognitive disorder. It is a disease is a progressive neurodegenerative disorder that leads to atrophy and the brain cells eventually die. 

Brain cell deterioration significantly affects the person's ability to function without being dependent on anyone. Initial symptoms of Alzheimer’s are minor memory loss and confusion. These early symptoms are frequently missed because they are misinterpreted as signs of the natural ageing process or exhaustion. As the disease progresses, the symptoms progress to a stage where it becomes impossible to function without proper care. The mild symptom of Alzheimer’s includes lack of spontaneity, subtle personality change, and minor disorientation.  The symptoms tend to get worse as the disease progresses. 

The symptoms of Alzheimer’s disease progress to the point where the patient begins to experience drastic personality changes as they become incapable of comprehending normal day-to-day activities. Patients lose cognitive abilities, exhibit repetitive behaviour, and have no control over their appetite. Patients also lack self-control and are completely dependent on caregivers for both voluntary and involuntary bodily functions such as bladder control and bowel movements, decreased response to the environment, emaciation, seizures, and so forth. 

The disease is idiopathic, and the exact cause is still to be known. However, Alzheimer’s disease can be caused by a variety of factors, including increasing age, genetic factors, Down syndrome, head trauma, insomnia, a poor lifestyle, mild cognitive impairment (MCI), and excessive alcohol and drug consumption. Although there is no current cure for Alzheimer’s disease, several new therapeutic techniques have been developed to combat the disease. The major diagnostics and therapeutics involved in the Alzheimer’s disease industry include the development of biomarkers for Alzheimer’s diagnosis. While some treatments may postpone clinical decline and improve cognition and function, disease progression and eventual cell death cannot be prevented with current treatments. 

The present treatments may assist in alleviating symptoms such as memory loss and confusion. The Alzheimer's disease market is expected to grow as more drugs are developed to cure and treat the disease. The rising awareness-raising initiatives by public and private organisations will influence the Alzheimer's disease market in the coming years.

Market Segmentation

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

The Alzheimer’s Disease Treatment is segmented into:

Based on drug class, the market is segmented into

• Cholinesterase Inhibitors
  • Donepezil
  • Rivastigmine
  • Galantamine

• N-Methyl-D-Aspartate (NMDA) Receptor Antagonist 
  • Memantine

• Others

Based on the diagnosis, the market is segmented into

• Psychometric Diagnosis

• Cerebrospinal Fluid Analysis
  • Amyloid And Tau Protein Analysis
    • Brain Imaging Tests

• Others

Based on the treatment channel, the market is bifurcated into

• Public

• Private

Based on age, the market is segmented into

• Elderly

• Adults

• Children

Based on the End User, the market is segmented into

• Hospital Pharmacy

• Retail Pharmacy

• E-commerce

Market Breakup by Region

• North America
  • United States of America
  • Canada
• Europe
  • United Kingdom
  • Germany
  • France
  • Italy
  • Others
• Asia Pacific
  • China
  • Japan
  • India
  • ASEAN
  • Australia
  • Others
• Latin America
  • Brazil
  • Argentina
  • Mexico
  • Others
• Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Nigeria
  • South Africa
  • Others

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Alzheimer’s Disease on a Global level

Alzheimer’s disease has a high prevalence in Europe and North America. According to various studies, the regional prevalence of Alzheimer’s disease varies based on socio-economic differences as well as cultural variations. The disease is highly prevalent in North America and the United States alone accounts for over five million cases of Alzheimer's disease. As Alzheimer’s has a high prevalence amongst the elderly population, the growing elderly population in the region is a major concern for disease prevention. North America held the largest market share by value in the disease industry due to the availability of advanced healthcare infrastructure and drug development studies. Alzheimer's disease is more common in women than men as the former lives are more extended than the latter.

The Ubiquity of Alzheimer’s Disease

Alzheimer’s, studies have showcased that there is a prevalence in developed countries than in developing. This was attributed to differences in the level of exposure to cerebrovascular risk factors like hypertension, smoking, obesity, and diabetes.  Europe had the second largest share of disease prevalence. Studies is Europe have equated high lower level of education to the high prevalence of the disease in the region. 

Recent Alzheimer’s disease metric research has showcased a rapid rise in the prevalence, incidence, mortality, and disability-adjusted life years (DALYs) rates globally, especially during the past three decades. 

Asia Pacific region also followed the global trend as the prevalence of dementia seems to be higher in developed countries, like Japan and Korea, than in countries with low incomes in Asia. Japan accounts for the highest prevalence of Alzheimer’s disease in the region. 

Currently, more than 25 million people in the world are affected by dementia, most of the patients suffering from Alzheimer’s disease, with around five million new cases occurring every year. 

Alzheimer’s Treatment in Development

Various clinical trials for Alzheimer’s are being developed and researched by multifarious healthcare organizations and pharma companies. These industry segments are trying to understand the disease mechanism, disease treatment. As there is no treatment for Alzheimer’s, clinical trials are also being conducted for developing care pathway and slowing down the disease progression. 

Despite the numerous constraints in hindrances, there have been some disease-modifying drugs that aim to slow down the progression of the disease. These drugs interfere with the progression of clinical symptoms, such as the accumulation of extracellular amyloid β plaques, together with intracellular neurofibrillary tangles, inflammation, cholesterol metabolism, iron deregulation, and oxidative damage, among other symptoms. The only aid so far has been significant changes in the lifestyle, including regular exercising. This is expected to pave way for the growth of the market for Alzheimer’s treatment in the healthcare industry. 

Various therapies are being explored through clinical trials to find drugs against tau protein, and β-secretase (BACE), which are responsible for the tangles, plaques, and deterioration of memory and cognition by meditating neurotransmitters like glutamate and acetylcholine. 

Although there has been no cure for the disease so far, the drug trial line up has been strong. Some of these drug’s trials might be successful and these drugs might reach the marketplace within the next decade. The Alzheimer’s disease market has been witnessing different key players conducting various trials.

One of the major industry players, Eli Lilly is conducting trials for six drugs that are in numerous phases of development. Another major healthcare conglomerate, Biogen is conducting clinical trials conducting trials for five drugs, which are in Phase 1, Phase 2, and Phase 3 clinical trials stages.

Other than Eli lily and Biogen, companies like Roche and Eisai are the major competitors in the industry in developing drugs and treatment methods for Alzheimer’s. Roche is developing a drug by using Genentech technology and is currently in phase 2 and phase 3 of the clinical trials. Eisai is also developing a treatment method in collaboration with Biogen. 

Therapeutic Landscape

Alzheimer’s disease is a devastating neurodegenerative disease leading to dementia. The disease industry has made significant progress over the last fifteen years. The causes of the disease are still not known, and the most prominent cause seems to be genetic and lifestyle factors. APOE4 gene is one of the most common genetic risks for the disease as there is high chance of disease development by lipid imbalances. There have been various competing theories based on amyloid, neurovascular, and tau to explain the factors causing the disease.

Glimpse of Treatment Cost

The cost of treatment for Alzheimer’s is very high. As the disease requires patient care as well as medical treatment. The Alzheimer’s therapeutic industry can be divided into pharmaceutical treatment as well as patient care. 

The treatment cost for Alzheimer’s is the highest in the United States in the North America region. Alzheimer’s treatment market was valued between 200 to 300 billion USD in 2020 in the United States alone. In the coming years this cost is also projected to reach more than 1.1 trillion USD. With the high potential value for disease treatment, there is a wide opportunity for healthcare industries in drug development, and novel diagnostics methods. The industry is expected to see growth opportunities, which are directed towards understanding disease mechanisms related to genetic risk factors of Alzheimer’s, both for patient stratification and assessment of therapeutic efficacy in clinical trials. Organizational characteristics such as size and proprietary status are the major industry driving factors influencing the propensity to supply specialty care in dedicated units for Alzheimer’s disease. There is also growing opportunities in nursing care facilities, as they are moving toward providing specialty care units partly as a response to a growing demand by industry key segments and to maintain a competitive edge in a stiffer market. 

Competitive Landscape

The report gives an in-depth analysis of the key players involved in the market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. The rising initiatives by public and private organizations to increase awareness will also play a huge role in increasing the competition in the Alzheimer’s disease market. The competition in the global market is growing owing to the incorporation of niche technologies disease treatment. The companies included in the market are as follows:

• F Hoffmann La Roche

• H. Lundbeck

• Zydus Lifesciences Ltd.

• Pfizer Inc

• Baxter International Inc.

• Abbvie, Inc.

• Eisai Co. Ltd.

• Merz Pharma

• AstraZeneca

• Eli Lilly and Company

• Teva Pharmaceutical Industries Ltd.

• ONO Pharmaceutical Industries Ltd.

• VTV Therapeutics

• Biogen

Key Highlights of the Report